Vital prognosis in HIV-infected patients has been improved by new therapies, leading to an increase in treatment and outpatient costs but lower inpatient care costs. The aim of the study was to compare the health care costs between 1992–1996 (first half) and 1996–2000 (second half) in HIV-infected patients at Rouen University Hospital. Hospitalization costs (including inpatient and outpatient care), infectious complication treatment and antiretroviral therapy costs were evaluated from a National Health Insurance viewpoint. Between 1992 and 2000, 1212 patients were admitted at least once. Total expenditure increased between the two periods from €13,660 to €27,567, i.e., a two-fold increase. During the same period, 125 deaths were avoided, and 3602 years of life were gained. The cost of one avoided death was €108,320 and the cost per life-year gained was €3776.
DelfraissyJF. Prise en charge thérapeutique des personnes infectées par le VIH — Rapport 1999. Paris: Médecine — Sciences Flammarion, 1999
3.
TorresRABarrM. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med1997;336:1531–2
4.
MoutonYAlfandariSValetteM. Impact of protease inhibitors on AIDS-defining events and hospitalisations in 10 French AIDS reference centres. AIDS1997;11:101–5
5.
MocroftAJohnsonMPhillipsA. Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS1996;10:1057–65
6.
JahnkeNMontessoriVHoggR. Impact of triple drug therapy on morbidity, mortality and cost. AIDS Revue1999;1:57–60
7.
CarosiGCasariSPalvariniL. Health resource utilisation in the era of HAART: An Italian experience. Interscience Conference on Antimicrobial Agents Chemotherapy1998;38:437
8.
CeboKAChaissonREFolkemerJG. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS1999;13:963–9.
9.
BozetteSAJoyceGMcCaffreyDF. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med2001;344:817–23
10.
Le PenCRozenbaumWDownsA. Effect of HAART on health status and hospital costs of severe HIV-infected patients: A modeling approach. HIV Clin Trials2001;2:136–45
11.
Le PenCRozenbaumWDownsA. A cost-effectiveness analysis of changes in therapeutic strategies in the treatment of HIV since 1996 [Article in French]. Thérapie2002;57:27–33
12.
SendiPPBucherHCHarrT. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients, Swiss HIV Cohort Study. AIDS1999;13:1115–22
13.
DelfraissyJF. Prise en charge thérapeutique des personnes infectées par le VIH — Mise à jour 2000. Paris: Médecine — Sciences Flammarion, 2000
14.
DariosecqJMGirardPM. Infection à VIH-mémento thérapeutique. Paris: Doin, 1998
15.
WallaceMRTaskerSAShinoharaYT. The changing economics of HIV care. AIDS Patient Care STDS2001;15:25–9
16.
WagnerGJRemienRHCarballo-DieguezA. Correlates of adherence to combination antiretroviral therapy among; members of HIV-positive mixed status couples. AIDS Care2002;14:105–9
17.
Anonyme. Retour d'informations clinico-epidé;miologiques. Paris: INSERM SC4. No 7, 2000
18.
MocroftAKatlamaCJohnsonAM. AIDS across Europe, 1994–98: The EuroSIDA study. Lancet2000;356:291–7
19.
KeiserPKvanliM.B.TurnerD. Protease inhibitor based therapy is associated with decreased HIV-relaled health care costs in men treated at a veterans administration hospital. I Acquir Immune Defic Syndr Hum Retroviral1999;20:28–33.
20.
FreedbergKALosinaEWeinsteinMC, The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med2001;344:824–31
21.
The diabetes control and complications trial research group. Lifetime benefits and costs of intensive therapy as practised in the diabetes control and complications trial. JAMA1996;276:1409–15
22.
MoattiJPHuardP. La juste évaluation des dépenses de santé. Pour la Science1995;218:34–41
23.
HoltgraveDRPinkertonSD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retroviral1997;16:54–62
24.
LittleSJHolteSRoutyJP. Antiretroviral-drug resistance among patients recently infected with HIV. N—Engl J Med2002;347:385–94
